Dermira raises $35m in series B
This article was originally published in Scrip
Executive Summary
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.
Clovis cashes in on ASCO boom with $170m offering
Clovis Oncology has announced a public offering to raise $170m on the back of the company's huge share price rise following its presentation at the American Society of Clinical Oncology annual meeting in Chicago 3 June.